Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Exact Sciences

The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It.

A revolution in oncology could help the 18 million cancer survivors in the U.S. and bolster Guardant Health, Natera and Exact Sciences.

Investors Business Daily

How Tariffs Are Rocking The 'Bubblegum And Shoestring' Medical Supply Chain

Tariff uncertainty has cast a pall over medical stocks. Re-shoring is possible, but expensive, leaving them in a "wait-and-see" pattern.

Investors Business Daily

Why Top 4% Guardant Health Surged To A 13-Month High And Topped A Profit-Taking Zone

Guardant Health stock hit a 13-month high Tuesday after Medicare officials agreed to pay for the company's colon cancer blood test.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Exact Sciences Stock Drops 11% Over Four Days. 'What Is Going On?'

Exact Sciences stock crumbled Thursday on its growing rivalry with Guardant Health and Natera in colon cancer screening.

Investors Business Daily

What 19 Analyst Ratings Have To Say About Exact Sciences

19 analysts have shared their evaluations of Exact Sciences (NASDAQ:EXAS) during the recent three months, expressing a mix of bullish and bearish perspectives.

Benzinga

Guardant Health Pops 13% On An 'Impressive' Beat Following Exact Sciences' Flop

Guardant Health stock jumped Thursday on an "impressive" third-quarter report following the launch of its cancer detection test, Shield.

Investors Business Daily

Exact Sciences Collapses On 'Alarming' Guidance Cut. Is The Growth Story Broken?

Exact Sciences stock collapsed Wednesday after the Cologuard maker reported light third-quarter sales and cut its full-year outlook.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Exact Sciences Stock Falls 29% On Weak Results, Downbeat Outlook

Exact Sciences stock fell sharply Tuesday after the company cut its full-year outlook and posted weaker-than-expected results.

Investors Business Daily

1 'Strong Buy' Healthcare Stock to Scoop Up After Its Latest FDA Win

This top-rated healthcare stock is poised for substantial growth after securing FDA approval for its innovative non-invasive cancer diagnostic.

Barchart

Exact Sciences Stock Rises After FDA Signs Off On New Cologuard

Exact Sciences stock rose Friday after the FDA approved the company's next-generation colon cancer detection test, Cologuard Plus.

Investors Business Daily

Why Exact Sciences, Up 27%, Is 'Coiled To Snap Back' After Quarterly Beat

Exact Sciences stock bounded higher Thursday after beating second-quarter expectations, signaling a return to growth for Cologuard.

Investors Business Daily

Guardant Health Jumps — As Exact Sciences Slumps — On A Key FDA Move For Blood Tests

Guardant Health stock jumped Friday after an FDA panel recommended the agency approval Guardant's blood-based colon cancer screening test.

Investors Business Daily

Exact Sciences Stock, A Cathie Wood Darling, Tumbles On 'Overblown' Growth Concerns

Exact Sciences stock tumbled early Thursday as fears of a sales slowdown spooked investors in the Cologuard maker.

Investors Business Daily

Exact Sciences, A Cathie Wood Stock, Surges As Rival Colon Cancer Test Pales

Exact Sciences stock surged Tuesday after the company's colon cancer-screening rival, Freenome, unveiled the results of a pivotal study.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Cathie Wood Darling Exact Sciences, And Rival Guardant Health, Dip On Colon Cancer Updates

Exact Sciences stock fell early Thursday after the company said its next-generation Cologuard beat a rival stool-based screening test.

Top News

Cologuard Classic: Golf Tournament Promotes Colon Cancer Awareness And Advocacy

The Cologuard Classic combines golf and advocacy to raise awareness about colon cancer screening, featuring top players and supporting survivors.

Investors Business Daily

Exact Sciences, A Cathie Wood Holding, Comes In Hot With Double-Digit Sales Growth

Exact Sciences, a large Cathie Wood holding, came in hot with double-digit sales growth. But EXAS stock reversed lower.

Investors Business Daily

Cathie Wood's Biggest Holdings Are Tumbling, Including Tesla

Cathie Wood's Ark Invest has big stakes in speculative plays such as Tesla and Coinbase. But even 2023's big winners are well off highs.

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

1 Cathie Wood Stock with 65% Upside Potential

This stock holds a spot in maverick investor Wood's flagship fund, and analysts agree the cutting-edge diagnostics specialist has plenty of growth potential from current levels.

Barchart

3 Cathie Wood Stocks Beating the Nasdaq This Year

The maverick fund manager catches a lot of heat for her stock picks, but these three ARKK standouts are absolutely crushing the broader Nasdaq Composite so far in 2023.

Investors Business Daily

Dow Jones Futures Fall On U.S. Debt Downgrade; AMD, ELF Lead 7 Earnings Movers

Futures fell as Fitch downgraded the U.S. debt rating. AMD and ELF Beauty were big earnings movers late

Investors Business Daily

Exact Sciences, A Cathie Wood Darling, Skids Despite A Sixth Big Quarter

Exact Sciences reported another quarter of strong growth, but screening sales missed whispered forecasts and EXAS stock plummeted Wednesday.

Investors Business Daily

This Cathie Wood Stock Is Outperforming Even Tesla

Cathie Wood has bet big on 10 stocks. Tesla stock has more than doubled in 2023, but it's not the strongest performer among Ark Invest's major holdings.

Investors Business Daily

The Wild Ride That Has Sent Exact Sciences 216% Higher Since October

Exact Sciences said the company's next-generation Cologuard outperformed the original test. EXAS stock seesawed on the news.

Investors Business Daily

Why Top 2% Stock Exact Sciences Is On An Eight-Month Hot Streak — And Just Hit A Profit-Taking Zone

The market for colon cancer screening is massive — and underserved. And that might be why EXAS stock is on an eight-month hot streak.

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.